Source link : https://www.newshealth.biz/health-news/fda-rejects-nk1r-antagonist-for-gastroparesis/
The FDA declined to approve tradipitant for adults with symptoms of gastroparesis, or delayed gastric emptying, drugmaker Vanda Pharmaceuticals announced on Thursday. Support for the neurokinin-1 receptor (NK1R) antagonist included a negative phase III trial and a positive phase II study involving patients with diabetic or idiopathic gastroparesis, along with data from an open-label trial […]
Author : News Health
Publish date : 2024-09-19 21:08:31
Copyright for syndicated content belongs to the linked Source.